close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XBiotech Inc. - Common Stock (NQ:XBIT)

2.570 +0.110 (+4.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about XBiotech Inc. - Common Stock

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
XBiotech Pauses Rheumatology program
Findings from recently completed Rheumatoid Arthritis Study raise questions 
From XBiotech Inc.
Via GlobeNewswire
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy 
From XBiotech Inc.
Via GlobeNewswire
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
From XBiotech Inc.
Via GlobeNewswire
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
(Phase II Multicenter Study is Proceeding Well with High Anticipation) 
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
From XBiotech Inc.
Via GlobeNewswire
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment 
From XBiotech Inc.
Via GlobeNewswire
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke 
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in France 
From XBiotech Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today